Tienan Zhu. Antiplatelet Therapy: the Role of Platelet Function Monitoring[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(2): 123-126. doi: 10.3969/j.issn.1674-9081.2018.02.006
Citation: Tienan Zhu. Antiplatelet Therapy: the Role of Platelet Function Monitoring[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(2): 123-126. doi: 10.3969/j.issn.1674-9081.2018.02.006

Antiplatelet Therapy: the Role of Platelet Function Monitoring

doi: 10.3969/j.issn.1674-9081.2018.02.006
More Information
  • Author Bio:

    Tel: 010- 69155027, Email:zhutn@pumch.cn

  • Received Date: 2017-12-18
  • Publish Date: 2018-03-30
  • Antiplatelet therapy is of proven benefit to arterial thrombotic diseases. Although antiplatelet agents are usually given on fixed dosages, there is great interindividual variability in pharmacodynamic response to antiplatelet medications. Patients with high on-treatment platelet reactivity are at increased risk for thrombotic events. On the contrary, low on-treatment platelet reactivity has been linked to a higher risk of bleeding. Personalized antiplatelet treatment strategies based on platelet function monitoring constitute a promising tool for the prevention of both thrombotic and bleeding events, but the conclusive evidence for improved clinical outcomes with such approaches is yet lacking. Up to now, whether routine laboratory monitoring of antiplatelet therapy is of clinical benefit is still controversial. This review discusses the causes of variability in the response to aspirin or clopidogrel and highlights the current position of platelet function testing in guiding personalized antiplatelet therapy.
  • loading
  • [1] Orme R, Judge HM, Storey RF. Monitoring antiplatelet therapy [J]. Semin Thromb Hemost, 2017, 43: 311-319. doi:  10.1055/s-0036-1597298
    [2] Michelson AD, Bhatt DL. How I use laboratory monitoring of antiplatelet therapy?[J]. Blood, 2017, 130: 713-721. doi:  10.1182/blood-2017-03-742338
    [3] Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease [J]. J Am Coll Cardiol, 2007, 50: 1822-1834. doi:  10.1016/j.jacc.2007.07.051
    [4] Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adeno-sine diphosphate associated with ischemia and bleeding [J]. J Am Coll Cardiol, 2013, 62: 2261-2273. doi:  10.1016/j.jacc.2013.07.101
    [5] Jovanovic L, Antonijevic N, Novakovic T, et al. Practical aspects of monitoring of antiplatelet therapy [J]. Semin Thromb Hemost, 2017, 43: 14-23. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=f94cca36d07f692d877ca43f77dcb8e1
    [6] Patrono C. The multifaceted clinical readouts of platelet inhibition by low-dose aspirin [J]. J Am Coll Cardiol, 2015, 66:74-85. doi:  10.1016/j.jacc.2015.05.012
    [7] Price MJ, Berger PB, Teirstein PS, et al.Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial [J]. JAMA, 2011, 305: 1097-1105. doi:  10.1001/jama.2011.290
    [8] Collet JP, Cuisset T, Rang'e G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting [J]. N Engl J Med, 2012, 367: 2100-2109. doi:  10.1056/NEJMoa1209979
    [9] Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial [J]. Lancet, 2016, 388: 2015-2022. doi:  10.1016/S0140-6736(16)31323-X
    [10] Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) [J]. Eur Heart J, 2014, 35: 2541-2619. doi:  10.1093/eurheartj/ehu278
    [11] Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions [J]. J Am Coll Cardiol, 2011, 58: e44-e122. http://www.researchgate.net/publication/281297740_ACCFAHASCAI_guideline_for_percutaneous_coronary_intervention_executive_summary_a_report_of_the_American_College_of_Cardiology_FoundationAmerican_Heart_Association_Task_Force_on_Practice_Guidelines_and
    [12] Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) [J]. Eur Heart J, 2017. doi:  10.1093/eurheartj/ehx419. [Epub ahead of print].
    [13] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会.抗血小板药物治疗反应多样性临床检测和处理的中国专家建议[J].中华心血管病杂志, 2014, 42: 986-991. doi:  10.3760/cma.j.issn.0253-3758.2014.12.002
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (246) PDF downloads(136) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return